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Abstract
Herpes simplex virus 1 (HSV-1) ICP0
2 mutants are interferon-sensitive, avirulent, and elicit protective immunity against HSV-
1( Virol J, 2006, 3:44). If an ICP0
2 mutant of herpes simplex virus 2 (HSV-2) exhibited similar properties, such a virus might be
used to vaccinate against genital herpes. The current study was initiated to explore this possibility. Several HSV-2 ICP0
2
mutant viruses were constructed and evaluated in terms of three parameters: i. interferon-sensitivity; ii. virulence in mice;
and iii. capacity to elicit protective immunity against HSV-2. One ICP0
2 mutant virus in particular, HSV-2 0DNLS, achieved an
optimal balance between avirulence and immunogenicity. HSV-2 0DNLS was interferon-sensitive in cultured cells. HSV-2
0DNLS replicated to low levels in the eyes of inoculated mice, but was rapidly repressed by an innate, Stat 1-dependent host
immune response. HSV-2 0DNLS failed to spread from sites of inoculation, and hence produced only inapparent infections.
Mice inoculated with HSV-2 0DNLS consistently mounted an HSV-specific IgG antibody response, and were consistently
protected against lethal challenge with wild-type HSV-2. Based on their avirulence and immunogenicity, we propose that
HSV-2 ICP0
2 mutant viruses merit consideration for their potential to prevent the spread of HSV-2 and genital herpes.
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Introduction
Herpes simplex virus 1 (HSV-1) or herpes simplex virus 2
(HSV-2) may cause primary genital herpes [1,2,3]. In contrast,
more than 90% of cases of recurrent genital herpes are caused by
HSV-2 [1,4]. Recurrent genital herpes is a physically superficial
disease in most cases, but often produces emotionally debilitating
effects [5,6,7]. Because HSV-2 is responsible for the bulk of
disease, an effective HSV-2 vaccine is sought that may stop the
spread of genital herpes.
HSV-1 and HSV-2 are similar viruses that share a nearly
identical set of ,75 co-linear genes distributed across 152 and
154 kbp dsDNA genomes, respectively. HSV-1 and HSV-2
establish life-long infections in their human hosts, and both viruses
persist by establishing latent infections in the human nervous
system. Infections with these viruses are exceedingly common;
HSV-1 infects ,4 billion people and HSV-2 infects ,1 billion
people [8]. Approximately 5% of HSV-2 infected individuals live
with genital herpes disease that recurs once every 3 to 12 months
[9,10]. HSV-2 infections spread to new individuals at a rate of
,20 million per year. An effective HSV-2 vaccine would be useful
in breaking this cycle, and protecting young adults from the 1 in 10
chance that they will acquire HSV-2 before they marry [4,11,12].
For decades, efforts to develop an HSV-2 vaccine have been
predicated on the assumption that a live-attenuated HSV-2 virus
would be too risky for use as a human vaccine, and safer
alternatives have been sought [13,14]. The non-replicating HSV-2
vaccines that have been most seriously considered are 1. HSV-2
subunit vaccines and 2. replication-defective HSV-2 viruses. The
immunodominant HSV-2 glycoprotein D (gD2) antigen has been
considered for its potential to serve as a subunit vaccine. After
more than a decade of testing in human clinical trials, it remains
unclear that vaccination with a gD2 subunit renders human
recipients immune to wild-type HSV-2 infections and/or genital
herpes [15,16]. One of the limitations of an HSV-2 subunit
vaccine is that vaccine recipients are only exposed to 1% of HSV-
2’s antigens (i.e., 1 of ,80 proteins). Replication-defective HSV-2
viruses offer the advantage that nearly all of HSV-2’s antigens may
be expressed at the site of inoculation and presented to CD8
+ T
cells in the context of the MHC class I pathway [17,18]. However,
it remains unclear if a replication-defective HSV-2 virus may
recapitulate the magnitude and duration to the immune response that
is elicited against a live, replicating virus such as wild-type HSV-2.
An HSV-2 vaccine should not only be safe, but it should also be
effective. For decades, live HSV-2 viruses have been largely
excluded from consideration as a genital herpes vaccine on the
grounds that a live-attenuated HSV-2 vaccine would be too
dangerous. However, this safety-based rationale is incongruous
with the 200-year history of viral vaccines. Approximately 75% of
the vaccines that have succeeded in preventing human viral
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parents have deemed the approach safe enough for the past 50
years to warrant the inoculation of hundreds of millions of children
with live, replicating viruses, and millions of human lives have
been spared from death or disfigurement as a result.
Historically, live-attenuated viruses have been our most effective
mode of vaccination. Originally, the word ‘vaccination’ specifically
meant to inject a person with live, replicating vaccinia virus in order
to elicit a cross-protective response that provided immunity against
the smallpox virus [19]. Most of our effective viral vaccines
emulate the original approach, and rely on inoculation of humans
with live viruses that establish mild or inapparent infections that
cross-protect against their more virulent counterparts that exist in
nature. Such live-attenuated viruses are the active ingredient in the
oral poliovirus vaccine, the MMR (mumps, measles, rubella)
vaccine, and the chickenpox and shingles vaccine [20,21,22].
Isolated reports have raised the possibility that a live-attenuated
HSV-2 vaccine might be feasible [23,24,25]. However, a live-
attenuated HSV-2 vaccine has not been systematically investigated
due to concerns surrounding the safety of administering a live a-
herpesvirus to millions of people [26].
Tens of millions of children have now been inoculated with the
live-attenuated Oka strain of varicella-zoster virus (VZV) [27].
Like HSV-1 and HSV-2, VZV is an a-herpesvirus that routinely
establishes life-long infections in the human nervous system [28].
The live VZV vaccine has proven safe and effective in preventing
the epidemic spread of chickenpox [20,27], and is now being used
to prevent the age-onset disease of ‘shingles’ caused by reactivated
VZV infections [29,30,31]. The success of the chickenpox vaccine
demonstrates that a live and appropriately attenuated a-herpes-
virus may be used to safely control a human disease. If this
principle may be expanded to include HSV-1 and HSV-2, then
genital herpes might also be prevented using a live-attenuated
HSV-2 virus as a vaccine. The feasibility of this proposal remains
unclear because it has not been investigated.
The ICP0 gene encodes a critical regulatory protein, infected cell
protein 0 (ICP0), which controls HSV-1’s balance between latency
and replication (reviewed in Ref. [32,33,34]). HSV-1 viruses that
bear null mutations in the ICP0 gene are acutely sensitive to
repression by interferon-a/b [35,36], are avirulent in immunocom-
petent miceand lymphocyte-deficient rag2
2/2 mice[37], and elicita
nearly sterilizing immune response against wild-type HSV-1 [37].
These studies have led us to predict that a live HSV-2 vaccine strain
may be derived by mutagenesis of HSV-2’s ICP0 gene [13,37].
The current study was initiated to test this hypothesis. Five
HSV-2 ICP0
2 mutant viruses were constructed and characterized
using a screening procedure designed to determine if any of these
mutant viruses achieved the type of balance between safety and
immunogenicity that should be expected of a live-attenuated
vaccine strain. We report that one HSV-2 ICP0
2 mutant virus in
particular, HSV-2 0DNLS, exhibited such properties. HSV-2
0DNLS was interferon-sensitive, avirulent in immunocompetent
animals, and elicited robust protection in recipients against later
exposures to wild-type HSV-2. Based on these results, we propose
that interferon-sensitive HSV-2 ICP0
2 mutant viruses warrant
consideration for their potential to prevent the spread of HSV-2
and genital herpes in the human population.
Results
Construction and characterization of HSV-2 ICP0
2
mutant viruses
Three regions of ICP0 are conserved between HSV-1 and
HSV-2; a RING finger-E3 ligase region [38], the region
surrounding the nuclear localization signal (NLS) and adjacent
phosphorylation sites [39,40], and a C-terminal oligomerization
domain [41,42] (Fig. 1B, Fig. S1). To obtain HSV-2 viruses that
varied in their level of attenuation, deletions were introduced into
the ICP0 gene that removed none, one, or all of ICP0’s conserved
regions (Fig. 1A, 1B). All HSV-2 ICP0
2 mutant viruses bore a
common deletion that replaced codons 19 to 104 of the ICP0 gene
with a green fluorescent protein (GFP) coding sequence. HSV-2 0D104
contained this one mutation, and thus encoded a GFP-tagged,
mutant protein that retained all of ICP0’s conserved regions
(Fig. 1A, 1B). A larger deletion in HSV-2 0DRING removed
codons 19 to 162, and thus removed several cysteine residues
necessary for ICP0’s E3 ligase activity [43] (Fig. 1A, 1B). HSV-2
0DNLS contained two deletions that removed codons 19 to 104
and codons 489 to 694 of the ICP0 gene. Thus, HSV-2 0DNLS
encoded a GFP-tagged protein that lacked ICP0’s NLS region and
a portion of the C-terminal oligomerization domain (Fig. 1A, 1B).
Finally, HSV-2 0D254 and HSV-2 0D810 contained deletions in
the ICP0 gene that resulted in expression of little more than GFP
from the ICP0 locus (Fig. 1A, 1B).
Southern blot analysis confirmed that each HSV-2 mutant virus
bore an insertion of GFP coding sequence in place of a deletion of
the expected size in the ICP0 gene (Fig. 1A, 1C). Western blot
analysis with a GFP-specific antibody confirmed that HSV-2
0D254 and HSV-2 0D810 encoded GFP-tagged, ICP0 peptides
that were only slightly larger than native GFP expressed by an
HSV-2 recombinant virus, HSV-2 MS-GFP (Fig. 1D, Fig. S2). As
expected, HSV-2 0D104 and HSV-2 0DNLS encoded their
respective 125 kDa and 85 kDa GFP-tagged proteins (Fig. 1D). In
addition, 5 lower MW peptides of 45–80 kDa also reacted with
GFP antibody (Fig. 1D). HSV-2 0DRING encoded an ,120 kDa
GFP-tagged protein, and only a single additional peptide was
observed (Fig. 1D). ICP0 ubiquitinates itself in a RING-finger-
dependent manner [44]; hence, most of the lower MW peptides
observed in cells infected with HSV-2 0D104 or 0DNLS appeared
to be the result of autoubiquitination and proteolytic turnover of
GFP-tagged ICP0 (Fig. 1D). Collectively, Southern and Western
blot analysis indicated that the intended mutations were
successfully introduced into the HSV-2 ICP0 gene.
ICP0 is essential for HSV-2’s resistance to interferon-a/b
HSV-1 ICP0
2 null viruses do not replicate efficiently in cells
that have been exposed to interferon (IFN)-a/b [36,45]. To
determine if HSV-2 ICP0
2 mutant viruses were also IFN-sensitive,
wild-type HSV-2 MS and HSV-2 ICP0
2 mutant viruses were
compared for their capacity to form plaques in monolayers of
ICP0-complementing L7 cells, non-complementing Vero cells, or
IFN-b-treated Vero cells. Wild-type HSV-2 MS (ICP0
+) formed
plaques with equal efficiency in Vero and ICP0
+ L7 cells, and
formed plaques 4-fold less efficiently in Vero cells treated with
IFN-b (Fig. 2A, 2C). HSV-2 0D104 was only modestly attenuated,
and formed plaques 12-fold less efficiently in Vero cells treated
with IFN-b relative to ICP0
+ L7 cells (Fig. 2C). In contrast, all
other HSV-2 ICP0
2 mutant viruses were acutely sensitive to IFN-
a/b. For example, HSV-2 0DNLS formed plaques 14-fold less
efficiently in Vero cells than ICP0
+ L7 cells, and formed plaques
3,300-fold less efficiently in Vero cells treated with IFN-b (Fig. 2B,
2C). Likewise, the HSV-2 ICP0
2 mutant viruses 0DRING, 0D254,
and 0D810 formed plaques 2,000- to 15,000-fold less efficiently in
IFN-b-treated Vero cells relative to ICP0
+ L7 cells (Fig. 2C).
The growth kinetics of wild-type HSV-2 MS and HSV-2 ICP0
2
mutant viruses were compared in monolayers of ICP0
+ L7 cells,
Vero cells, or IFN-b-treated Vero cells inoculated with 0.1 viral
plaque-forming units(pfu)percell.Wild-typeHSV-2grewtosimilar
HSV-2 ICP0
2 Mutant Viruses
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replication were delayed in IFN-b-treated cells, but HSV-2 MS
achievedafinaltiterthat wasonly6-foldlowerthan thatobservedin
ICP0
+ L7 cells (Fig. 3A). HSV-2 0D104 was modestly attenuated,
andgrewto 100-foldlowertiters inIFN-b-treatedVero cellsrelative
to ICP0
+ L7 cells (Fig. 3B). In contrast, the other HSV-2 ICP0
2
mutant viruses 0DRING, 0D254, 0D810, and 0DNLS were acutely
sensitive to IFN-a/b, and grew to 5,000- to 31,000-fold lower titers
Figure 1. Description of HSV-2 ICP0
2 mutant viruses. (A) Mutations in the HSV-2 ICP0 gene. Schematics indicate the relative size and location
of a GFP-coding sequence that replaced codons 19–104 in all HSV-2 ICP0
2 mutants, as well as the size and location of secondary deletions in HSV-2
0DRING, 0DNLS, 0D254, or 0D810. (B) Regions of ICP0 conserved between HSV-1 and HSV-2 are color-coded above, and below is shown the effects of
deletions on ICP0’s conserved RING finger region, nuclear localization signal (NLS) region, and/or oligomerization domain. (C) Southern blot analysis
of SacI – StuI digested DNA harvested from cells that were uninfected (UI) or were inoculated with 2.5 pfu per cell of each indicated HSV-2 virus.
Replicate Southern blots were hybridized with an ICP0 exon 2-specific oligonucleotide (shown on left) or a GFP-specific oligonucleotide (shown on
right). The approximate locus to which the ICP0-specific and GFP-specific probes hybridized is depicted in panel A. (D) Western blot analysis of
proteins harvested from cells that were uninfected (UI) or were inoculated with 2.5 pfu per cell of each indicated HSV-2 virus. GFP or chimeric ICP0
proteins bearing a GFP tag were labeled with rabbit polyclonal GFP-specific antibody. Molecular weight markers are shown on the right.
doi:10.1371/journal.pone.0012251.g001
HSV-2 ICP0
2 Mutant Viruses
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+ L7 cells (Fig. 3C–F). In
the absence of IFN-b, HSV-2 0D254 and 0D810 replicated poorly
in untreated Vero cells and achieved final titers of less than 10
4 pfu/
ml (Fig. 3D, 3E). In contrast, HSV-2 0D104, 0DRING, and 0DNLS
each replicated to titers of greater than 10
5 pfu per ml in untreated
Vero cells (Fig. 3B, 3C, and 3F). Thus, HSV-2 0DRING and
0DNLS were the only HSV-2 ICP0
2 mutant viruses that were IFN-
sensitive and retained the capacity to replicate with reasonable
efficiency in cells that did not provide wild-type ICP0 in trans.
HSV-2 0DNLS is severely attenuated relative to its ICP0
+
parent virus, HSV-2 MS
A dose of 500 or more pfu of wild-type HSV-1 readily
establishes productive infections in the eyes of mice, whereas 20-
fold higher doses of HSV-1 ICP0
2 mutant viruses are required to
establish a productive infection in mouse eyes [46]. To determine
the relative doses of wild-type HSV-2 or HSV-2 ICP0
2 mutant
virus required to establish a productive infection in mouse eyes,
outbred ICR mice were inoculated bilaterally with 0.8, 4, 20, or
Figure 2. Plaque assay evaluation of interferon-sensitivity. (A and B) Photographs of monolayers of ICP0
+ L7 cells versus Vero cells treated
with interferon-b (IFN-b, 200 U/ml), which were inoculated with 1.0-log dilutions of (A) wild-type HSV-2 MS or (B) HSV-2 0DNLS. (C) Reductions in the
efficiency of plaque formation of each virus in untreated Vero cells or IFN-b-treated Vero cells relative to fully permissive monolayers of ICP0
+ L7 cells
(mean 6 sem reduction based on n=3 plaque assays per group). A double asterisk (**) denotes p,0.001 regarding the probability, p, that each HSV-
2 ICP0
2 mutant virus formed plaques in IFN-b-treated Vero cells with the same efficiency as wild-type HSV-2.
doi:10.1371/journal.pone.0012251.g002
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0DNLS (n=8 per virus per dose). At all viral doses tested, wild-
type HSV-2 MS established robust infections that led to HSV-2
shedding in mouse eyes by Day 2 post-inoculation (p.i.) and
produced overt periocular disease by Day 5 p.i. (Fig. 4A, 4B).
Wild-type HSV-2 MS infections were lethal in 31 of 32 ICR mice
(Fig. 4C). These results were consistent with independent tests in
which the 50% lethal dose (LD50) of HSV-2 MS was found to be
,200 pfu per eye (not shown).
HSV-2 0DNLS required higher doses of virus to establish a
productive infection in outbred ICR mice. At doses of 800 or
4,000 pfu per eye, less than 50% of mice inoculated with HSV-2
0DNLS shed virus on Day 2 p.i. (Fig. 4A). However, at doses of
20,000 or 100,000 pfu per eye, ocular shedding of HSV-2
0DNLS was observed in all mice on Day 2 p.i. (Fig. 4A). Mice
inoculated with HSV-2 0DNLS remained indistinguishable
from uninfected mice between Days 5 and 60 p.i. (Fig. 4B, 4D).
Therefore, the LD50 of HSV-2 0DNLS was at least 500 times
greater than HSV-2 MS in an eye model of infection. Based on
these results, a dose of 100,000 pfu per eye was used to
inoculate mice with HSV-2 ICP0
2 mutant viruses in subsequent
tests.
Figure 3. Replication efficiency of wild-type HSV-2 versus HSV-2 ICP0
2 mutant viruses. Titers of (A) wild-type HSV-2 MS, (B) HSV-2 0D104,
(C) HSV-2 0DRING, (D) HSV-2 0D254, (E) HSV-2 0D810, or (F) HSV-2 0DNLS at times after inoculating ICP0
+ L7 cells, Vero cells, or interferon-b-treated
Vero cells with 0.1 pfu per cell. At each indicated time point, cultures were transferred from 37uCt o280uC, and titers of infectious virus were
determined upon thawing by a microtiter plaque assay. The mean 6 sd of viral titer at each time point (n=2 per data point) is plotted as a function
of time. Arrows on the right of each graph represent the antilogarithm (10
x) of the difference at 48 hours p.i. between viral titer in ICP0
+ L7 cells
versus interferon-b-treated Vero cells. Each graph is a representative result from 2 to 3 independent experiments.
doi:10.1371/journal.pone.0012251.g003
HSV-2 ICP0
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12251Figure 4. The 0DNLS mutation renders HSV-2 avirulent in outbred ICR mice. (A) HSV-2 shedding from the eyes of mice on Day 2 following
bilateral ocular inoculation with 0.8, 4, 20, or 100 thousand pfu/eye of HSV-2 MS or HSV-2 0DNLS (n=8 mice per group). (B) Representative
photographs of naı ¨ve mice on Day 5 following ocular inoculation with 100,000 pfu/eye of wild-type HSV-2 MS versus the HSV-2 ICP0
2 mutant virus,
HSV-2 0DNLS. (C and D) Duration of survival of naı ¨ve mice following ocular inoculation with 0.8, 4, 20, or 100 thousand pfu/eye of (B) HSV-2 MS or (C)
HSV-2 0DNLS (n=8 mice per virus per dose; Sn=32 mice per virus). A single asterisk (*) denotes p,0.05, and a double asterisk (**) denotes p,0.001
regarding the probability, p, that HSV-2 shedding or survival was equivalent in groups of mice inoculated with the same dose of HSV-2 MS or HSV-2
0DNLS.
doi:10.1371/journal.pone.0012251.g004
HSV-2 ICP0
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2 mutant viruses
establish inapparent infections
The efficiency of replication of HSV-2 ICP0
2 mutant viruses
was compared to wild-type HSV-2 following inoculation of the
right eye with a viral dose of 100,000 pfu per eye (Fig. 5). To
ensure that a subset of mice survived infection with wild-type
HSV-2, one group of HSV-2 MS-infected mice was aggressively
treated with acyclovir (ACV) both orally and intraperitoneally
between Days 23 and +20 p.i. to limit viral spread and
pathogenesis [47,48,49]. All mice inoculated with HSV-2 MS
(ICP0
+) shed more than 3,000 pfu from the right eye on Day 1 p.i.,
and ACV treatment only modestly reduced HSV-2 shedding on
Days 2 and 3 p.i. (Fig. 5A). Each of the five mutations in HSV-2’s
ICP0 gene resulted in a significant reduction of HSV-2 shedding
between Days 1 and 3 p.i. (Fig. 5A, 5B). Specifically, mice
inoculated with HSV-2 0D254, 0D810, or 0DRING shed less than
100 pfu per eye between Days 1 and 3 p.i. (Fig. 5A, 5B). Likewise,
mice inoculated in the right eye with HSV-2 0D104 or HSV-2
0DNLS shed peak titers of ,300 pfu per eye on Day 2 p.i.
(Fig. 5B).
Expression of GFP-tagged, mutant ICP0 was visualized in
corneas at 60 hours p.i. by fluorescent microscopy (Fig. 5C). All
corneas inoculated with HSV-2 ICP0
2 mutant viruses exhibited at
least small foci of cells expressing GFP-tagged, mutant ICP0
(Fig. 5C; n=25 eyes observed per group). However, corneas
inoculated with HSV-2 0D104 or HSV-2 0DNLS contained wider
tracts of GFP
+ cells that were consistently .10 cells across
(Fig. 5C).
The frequency of survival of HSV-2 infected mice was
compared on Day 30 p.i. In untreated mice, ocular inoculation
with HSV-2 MS was uniformly lethal by Day 8 p.i. (Fig. 5D).
Aggressive use of ACV reduced mortality, and hence 21 of 30
ACV-treated mice survived HSV-2 MS infection until Day 30 p.i.
(Fig. 5D). HSV-2 0D104 was modestly attenuated, and thus mice
inoculated with HSV-2 0D104 survived 4 days longer than mice
inoculated with wild-type HSV-2 MS (i.e., duration of surviv-
al=1161 days p.i.). Nonetheless, only 1 of 25 mice survived
ocular inoculation HSV-2 0D104 (Fig. 5D). In contrast, 25 of 25
mice survived inoculation of the right eye with HSV-2 0DRING,
0D254, 0D810, or 0DNLS, and these mice remained disease-free
between Days 5 and 60 p.i. (Fig. 5D). Therefore, all HSV-2 ICP0
2
mutant viruses that were IFN-sensitive in cell culture (Fig. 2C)
were also avirulent in mice (Fig. 5D).
Mice inoculated with HSV-2 0DNLS are consistently
protected against wild-type HSV-2
HSV-2-specific IgG levels and protective immunity were
compared among the 100% of mice that survived inoculation
with HSV-2 ICP0
2 mutant viruses and the 70% of ACV-treated
mice that survived primary infection with wild-type HSV-2 MS
(Fig. 5D). Mice were bled on Day 60 p.i. and sera were tested for
the presence of IgG antibody against recombinant HSV-2
glycoprotein D (gD2) [50]. Dilutions of pooled HSV-2 antiserum
defined the quantitative relationship between color development
and gD2-antibody abundance (r
2=1.00; Fig. S3). The serum of
naı ¨ve mice defined the background of the assay, and HSV-2 MS
latently infected mice served as a positive control group that
should possess bona fide immunity to secondary HSV-2 infection
(Fig. 6A). HSV-2 MS latently infected mice possessed levels of
gD2-antibody that were ,1,350-fold above background (Fig. 6A,
p,0.001). Only ,50% of mice inoculated with HSV-2 0DRING,
0D254, or 0D810 possessed detectable gD2-antibody, and thus
their gD2-antibody responses did not significantly differ from
background (Fig. 6A; p.0.05). In contrast, the level of gD2-
antibody in HSV-2 0DNLS-inoculated mice was an average 53-
fold above background, and thus represented 4% of that observed
in HSV-2 MS latently infected mice (Fig. 6A; p,0.001).
On Days 70 and 80 after inoculating the right eye with HSV-2
ICP0
2 mutant viruses, mice were secondarily challenged in the
left eye with 500 times the LD50 of HSV-2 MS (i.e., 100,000 pfu
per eye). The summated results of these two challenge
experiments are presented (Sn=16 mice per group). As
expected, 060% of naı ¨ve mice survived for more than 8 days
p o s t - c h a l l e n g e( F i g .6 B ) .C o n sistent with their robust gD2-
antibody responses, 10060% of HSV-2 MS latently infected
mice survived superinfection of the left eye with HSV-2 MS,
and did not exhibit any symptoms of disease following challenge
(Fig. 6B). Mice inoculated with HSV-2 0DRING, 0D254, or
0D810 were not consistently protected against wild-type HSV-2
MS challenge, and their survival rates were 70610%, 50620%,
and 40620%, respectively (Fig. 6B). In contrast, 10060% of
mice inoculated with HSV-2 0DNLS survived lethal challenge
w i t hH S V - 2M S ,a n d1 1o f1 6o ft h e s em i c es u r v i v e dd i s e a s e -
free for 30 days post-challenge (Fig. 6B). Therefore, HSV-2
0DNLS was the only virus tested that consistently 1. replicated
a tt h es i t eo fi n o c u l a t i o n ,2. established an inapparent infection
in mice, and 3. elicited robust protectioni nm i c ea g a i n s tl a t e r
exposures to wild-type HSV-2.
The attenuated in vivo phenotype of HSV-2 ICP0
2
mutant viruses is Stat 1-dependent
HSV-2 0DNLS and HSV-2 0DRING were IFN-sensitive in
cultured cells and avirulent in mice (Fig. 2, 3, 5). To determine if
these phenotypes were causally related, viral replication and
disease were compared in i. wild-type strain 129 mice, ii.
lymphocyte-deficient rag2
2/2 mice, or iii. IFN-signaling-deficient
stat1
2/2 mice. Regarding the latter group, absence of the signal
transducer and activator of transcription 1 (Stat 1) results in a
signaling defect in which ligand binding to IFN receptors fails to
induce the transcription of the .300 IFN-stimulated genes that
mediate the ‘antiviral state’ [51,52,53]. Mice were inoculated
bilaterally with 100,000 pfu/eye of HSV-2 MS, 0DNLS, or
0DRING, and HSV-2 shedding was compared across all groups of
mice on Day 2 p.i. (Fig. 7A–C). Wild-type strain 129 mice shed
,1,600 pfu/eye of wild-type HSV-2 MS. In contrast, strain 129
mice inoculated with HSV-2 0DNLS or HSV-2 0DRING shed
,50 and 7 pfu/eye, respectively (Fig. 7A). Lymphocyte-deficient
rag2
2/2 knockout mice inoculated with these viruses exhibited an
equivalent pattern of HSV-2 shedding on Day 2 p.i. (Fig. 7B).
Hence, the restricted pattern of HSV-2 0DNLS and 0DRING
shedding from mouse eyes was not dependent on host lymphocytes
(Fig. 7A vs 7B). In contrast, stat1
2/2 mice shed ,1,500 pfu/eye of
both wild-type HSV-2 MS and HSV-2 0DNLS on Day 2 p.i.
(Fig. 7C; p.0.05). Likewise, stat1
2/2 mice shed ,200 pfu/eye of
HSV-2 0DRING, which represented a 30-fold increase in HSV-2
0DRING shedding relative to strain 129 mice (Fig. 7A vs 7C).
Thus, an innate, Stat 1-dependent host response severely restricted
HSV-2 0DNLS and 0DRING shedding in strain 129 mice and
rag2
2/2 mice on Day 2 p.i..
Disease and survival were compared among mice inoculated
with HSV-2 MS, 0DNLS, or 0DRING. As expected, HSV-2 MS
produced fatal encephalitis in all mice within 8 days p.i.
( F i g .7 D – F ) .H S V - 20 DNLS and 0DRING established inappar-
ent infections in 100% of strain 129 mice (Fig. 7D). HSV-2
0DNLS and 0DRING produced infections that slowly pro-
gressed towards lethal disease in rag2
2/2 mice (Fig. 7E). HSV-2
0DNLS infection of rag2
2/2 mice progressed to a fatal condition
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PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12251Figure 5. Interferon-sensitive HSV-2 ICP0
2 mutant viruses produce inapparent infections in mice. (A) HSV-2 shedding from the right
eyes of mice inoculated with 100,000 pfu/eye of wild-type HSV-2 MS which were untreated or were treated with the antiviral drug acyclovir (ACV), as
compared to mice inoculated in the right eye with (A) HSV-2 0D254 or HSV-2 0D810 or (B) HSV-2 0D104, HSV-2 0DNLS, or HSV-2 0DRING (n=15 per
group). ACV-treated mice were i. intraperitoneally administered 30 mg/kg ACV on Days 21, 0, 1, and 3 p.i., and were ii. orally administered 1 mg/ml
ACV in their drinking water from Days 23t o+20 p.i. A double asterisk (**) denotes p,0.001 regarding the probability, p, that viral shedding on a
given day was equivalent to HSV-2 MS-infected mice that received no ACV. (C) Representative sites of GFP-tagged ICP0 mutant protein expression in
mouse corneas inoculated with HSV-2 ICP0
2 mutant viruses at 60 hours p.i. (D) Mean 6 sd frequency of survival following inoculation with wild-type
HSV-2 MS or HSV-2 ICP0
2 mutant viruses in two independent experiments, as determined on Day 30 p.i. (Sn=25 mice per group). A double asterisk
(**) denotes p,0.001 regarding the probability, p, that the frequency of survival was equivalent to HSV-2 MS-infected mice that received no ACV.
doi:10.1371/journal.pone.0012251.g005
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2/2 mice between Days 18 and 50 p.i. (Fig. 7E).
In contrast, HSV-2 0DRING infection was fatal in only 2 of 10
rag2
2/2 mice over a 100-day observation period (Fig. 7E).
Presumably, the slower rate at which HSV-2 0DRING infection
caused disease in rag2
2/2 mice reflected a more severe defect in
the mutant ICP0
DRING protein, as ICP0’s RING finger domain
is essential for all of ICP0’s known activator functions
[32,33,34]. In contrast, loss of IFN-signaling in stat1
2/2 mice
was associated with more rapid disease progression. Stat1
2/2
mice succumbed to HSV-2 0DNLS or 0DRING infection
between Days 9 and 18 p.i. (Fig.7 F ) .T h u s ,t h ea t t e n u a t e d
phenotype of HSV-2 ICP0
2 mutant viruses was only observed in
animals that possessed the capacity to mount an innate, Stat 1-
dependent host antiviral response [35,37,54].
HSV-2 0DNLS infections fail to spread from the site of
inoculation
We were interested in clarifying how HSV-2 0DNLS consis-
tently replicated in mouse eyes without producing disease. We
considered the possibility that the 0DNLS mutation might reduce
the spread of HSV-2 0DNLS infection. To test this hypothesis, we
compared the spread of HSV-2 0DNLS (ICP0
2) infection across
mouse faces relative to an ICP0
+ virus that also expressed a
fluorescent marker, HSV-2 MS-GFP (Fig. S2).
On Day 2 after bilateral inoculation with 100,000 pfu per eye of
HSV-2 MS-GFP, GFP expression was only observed at the site
of inoculation (Fig. 8A, 8B; Fig. S4). On day 4 p.i., circular foci
of HSV-2 MS replication (GFP
+ cells) were evident on the noses of
mice, and these circular lesions enlarged and merged by Day 6 p.i.
(Fig. 8B). This rapid spread of HSV-2 MS-GFP infection was
accompanied by intense inflammation of the epithelium, and was
rapidly followed by fatal encephalitis.
On Day 2 after bilateral inoculation with 100,000 pfu/eye of
HSV-2 0DNLS, GFP expression was only observed at the site of
inoculation (Fig. 8A, 8B; Fig. S4). HSV-2 0DNLS did not visibly
spread from the site of inoculation, and thus GFP
+ cells were not
observed in the eyes of mice or in the periocular epithelium on
Days 4, 6, or 8 p.i. (Fig. 8B, Fig. S4; Day 8 not shown). Thus,
HSV-2 0DNLS replicated briefly at the site of inoculation, but
failed to spread or cause visible inflammation and disease.
Discussion
HSV-2 ICP0
2 mutant viruses that are interferon-sensitive
are severely attenuated in vivo
Prior studies have established that HSV-1 ICP0
2 mutant viruses
are interferon-sensitive, avirulent, and elicit protective immunity
against HSV-1 [37]. Based on these observations, we have inferred
that HSV-2 ICP0
2 mutant viruses might be useful as a live-
attenuated vaccine to prevent genital herpes [13,37]. Understand-
ably, enthusiasm for this proposal has been limited by the absence
of data describing HSV-2 ICP0
2 mutant viruses. The results of the
current study address this gap in knowledge.
HSV-2 MS infection of the eye is almost invariably lethal in naı ¨ve
ICR mice. In contrast, recombinant HSV-2 ICP0
2 mutant viruses
that were IFN-sensitive (Fig. 2, 3) were also avirulent in ICR mice
(Fig. 4, 5). Hence, mutations in the ICP0 gene are sufficient to
attenuate even a highly virulent HSV-2 strain such as MS. One
HSV-2 MS-derived ICP0
2 mutant, HSV-2 0D104, was not
attenuated and produced lethal disease in 24 of 25 mice (Fig. 5D).
Inhindsight,thisoutcomewaspredictablebasedonHSV-2 0D104’s
resistance to IFN-inducible repression in cultured cells (Fig. 2, 3).
The correlation between IFN-sensitivity and avirulence is unlikely
to be a coincidence. HSV-1 ICP0
2 mutant viruses are avirulent in
immunocompetent mice, but acquire the ability to replicate
efficiently and cause disease when host IFN signaling pathways
are compromised [35,37]. Based on this precedent, we were able to
correctly predict that the avirulent phenotype of HSV-2 0DNLS
would be dependent on the IFN-signal transducing factor, Stat 1
(Fig. 7). Thus consistent with the established properties of HSV-1
ICP0
2 viruses, the IFN-induced antiviral state appears to be
essential to the avirulent phenotype of IFN-sensitive HSV-2 ICP0
2
mutant viruses in immunocompetent animals.
Are the phenotypes of mutant HSV-2 viruses a
consequence of mutations in the ICP0 gene?
Four lines of evidence indicate that the phenotypes of HSV-2
0DNLS are a consequence of the intended mutation in the ICP0
Figure 6. Inoculation with HSV-2 0DNLS imparts protective
immunity against HSV-2. (A) Mean 6 sem titer of serum IgG
antibody specific for HSV-2 glycoprotein D (gD2), as determined by
ELISA on 1:100 dilutions of mouse serum (n=20 per group). (B) Mean 6
sd of the frequency of survival of mice until 30 days after challenge of
the left eye with a dose of 100,000 pfu/eye of HSV-2 MS (n=8 mice per
group per test62 tests; Sn=16 per group). A single asterisk (*) denotes
p,0.05, and a double asterisk (**) denotes p,0.001 regarding the
probability, p, that the survival frequency of each group was equivalent
to naı ¨ve mice.
doi:10.1371/journal.pone.0012251.g006
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Western blot analysis verify that the predicted genetic change was
introducedintothe ICP0locusofHSV-20D104,0DRING,0DNLS,
0D254, and 0D810 (Fig. 1). Second, the phenotypes of IFN-
sensitivity and avirulence are shared by four independent HSV-2
ICP0
2 mutant viruses; HSV-2 0DRING, 0DNLS, 0D254, and
0D810. It is improbable that four independent HSV-2 ICP0
2
mutant viruses would each acquire the expected phenotypes of IFN-
sensitivity and avirulence based on secondary mutations randomly
scattered throughout portions of the HSV-2 genome outside of the
ICP0 locus. Third, it was previously predicted that HSV-2 ICP0
2
mutant viruses should be IFN-sensitive and avirulent [13,37] based
on the fact that multiple HSV-1 ICP0
2 mutant viruses exhibit these
phenotypes [35,36,45]. Finally, whatever genetic defect impairs the
replication of HSV-2 0DRING, 0DNLS, 0D254, and 0D810 in
Vero cells is functionally complemented when wild-type ICP0 is
provided in trans from the ICP0
+ Vero-derived cell line, L7 cells
(Fig. 3). Therefore, mutations within the ICP0 gene of HSV-2
0DNLS appear to be responsible for the observed phenotypes of
IFN-sensitivity and avirulence.
Figure 7. HSV-2 ICP0
2 mutant viruses are repressed by a Stat 1-dependent host response. (A–C) Viral shedding on Day 2 p.i. from the
eyes of (A) wild-type strain 129 mice, (B) lymphocyte-deficient rag2
2/2 mice, or (C) IFN-signaling-deficient stat1
2/2 mice inoculated bilaterally with
100,000 pfu/eye of wild-type HSV-2 MS, HSV-2 0DNLS, or HSV-2 0DRING (n=10 mice per group). A single asterisk (*) denotes p,0.05 and a double
asterisk (**) denotes p,0.001 regarding the probability, p, that viral shedding was equivalent to HSV-2 MS shedding in the same strain of mice. (D–F)
Duration of survival of (D) strain 129 mice, (E) rag2
2/2 mice, or (F) stat1
2/2 mice following inoculation with wild-type HSV-2 MS, HSV-2 0DNLS, or HSV-
20 DRING (n=10 mice per group). A double asterisk (**) denotes p,0.001 regarding the probability, p, that the duration of survival was equivalent to
HSV-2 MS-infected mice of the same mouse strain.
doi:10.1371/journal.pone.0012251.g007
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2 mutant viruses that lack ICP0’s RING finger
region are overattenuated
HSV-2 ICP0
2 mutant viruses that included deletions of ICP0’s
RING finger domain were avirulent, but did not elicit consistent
protection against HSV-2 (Fig. 6B). Thus, deletions in ICP0’s
RING finger region produced HSV-2 viruses that appeared to be
overattenuated, and not particularly likely to succeed as a live-
attenuated HSV-2 vaccine strain. In contrast, HSV-2 0DNLS
exhibited the properties of a desirable live-attenuated HSV-2
vaccine strain. HSV-2 0DNLS consistently replicated at sites of
ocular inoculation, and was avirulent in immunocompetent mice.
Due to its consistent replication, HSV-2 0DNLS consistently
stimulated an immune response in recipient mice, as measured by
IgG antibodies against HSV-2’s immunodominant gD antigen,
and protective immunity against wild-type HSV-2 (Fig. 6).
The results suggest that HSV-2 replication at the site of
immunization may be proportional to the magnitude of the
resulting immune response. For example, mice inoculated with
HSV-2 0DRING shed peak titers of virus that were ,1% of the
peak titers shed by HSV-2 MS-infected mice and mounted gD2-
antibody responses that were ,0.5% of that in HSV-2 MS-
infected mice (Fig. 5, 6). Likewise, mice inoculated with HSV-2
0DNLS shed peak titers of virus that were 10-fold higher than the
peak titer of virus shed by HSV-2 0DRING-infected mice, and
mounted a gD2-antibody response that was ,10-fold greater than
HSV-2 0DRING and which was 1/25
th of that elicited by HSV-2
MS (Fig. 5, 6). Therefore, the average peak titer of virus shed
following inoculation (Fig. 5A, 5B) was roughly predictive of the
average gD2-antibody response observed on Day 60 p.i. (Fig. 6A).
Importantly, serum levels of gD2-antibody correlated with
functional protection against HSV-2 MS challenge (Fig. 6A vs 6B).
Correlation between gD2-antibody titers and protective
immunity against HSV-2?
When HSV-2 gD has been used as a subunit vaccine in human
clinical trials, the potency of the resulting gD2-antibody response
does not correlate with protective immunity against HSV-2
[55,56,57]. This observation appears to contradict our finding
that mice immunized with live HSV-2 viruses generate a
protective immune response that varies in proportion to serum
levels of gD2-antibody (Fig. 6A, 6B). Two explanations may
resolve this discrepancy. First, mouse IgG antibodies against HSV-2
Figure 8. HSV-2 0DNLS replicates at the site of inoculation, but fails to spread. (A) Sites of GFP expression (arrows), as visualized on Day 2
p.i., in the eyes of ICR mice inoculated with 100,000 pfu/eye of HSV-2 MS-GFP or HSV-2 0DNLS. (B) Progression of the spread of GFP expression across
the faces of mice inoculated with HSV-2 MS-GFP or HSV-2 0DNLS as visualized on Days 2, 4, and 6 p.i. These experiments were performed on n=3
mice per group, and the progression of infection is shown in a single representative mouse per group.
doi:10.1371/journal.pone.0012251.g008
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[58]. Thus, the correlation between gD2-antibody titers and
protection against HSV-2 challenge may be an artefact of the
mouse model used in this study. A second possibility is that HSV-2
gD subunit vaccines may be only weakly protective against HSV-2
infections regardless of the magnitude of the antibody response
elicited against the gD2 subunit. We favor the latter explanation
for two reasons.
First, immunization with an HSV-2 gD subunit vaccine is the
equivalent of vaccinating an animal with ,1% of HSV-2 (i.e., 1 of
80 HSV-2 proteins). In contrast, immunization with a live virus
such as HSV-2 0DNLS may drive the clonal expansion of B and T
lymphocytes specific for nearly the entire proteome of HSV-2,
which consists of thousands of combinations of 6 to 10 amino-acid
epitopes distributed across HSV-2’s 80 proteins. The increased
breadth of the immune response against a live-attenuated virus may
explain why this mode of vaccination has been so effective in
preventing severe viral diseases such as smallpox and measles.
Second, gD2-antibody responses provide a robust index of
protective immunity against HSV-2 when mice are immunized
with a live HSV-2 virus, but this is not the case when mice are
immunized with an HSV-2 gD subunit vaccine (unpublished data
of W. Halford). For example, mice immunized with an HSV-2 gD
subunit vaccine mount a gD2-antibody response that is 20-fold
greater than that elicited by immunization of mice with HSV-2
0DNLS (unpublished data of W. Halford). However, only 3 of 45
gD-immunized mice survive ocular or vaginal challenge with wild-
type HSV-2, whereas 119 of 120 0DNLS-immunized mice survive
ocular or vaginal challenge with wild-type HSV-2 (unpublished
data of W. Halford). Based on our experience in mice, we infer
that when a live HSV-2 virus is used as the immunogen, then
serum levels of gD2-antibody provide a reliable index of protective
immunity against HSV-2. It remains to be determined if this
inference holds true in other species.
HSV-2 latently infected mice as a positive control for
vaccine-challenge studies
Most HSV-2 vaccine-challenge study designs only compare
immunity to HSV-2 in vaccinated animals versus naı ¨ve controls
[16,18,59,60,61]. Such study designs establish that an HSV-2
vaccine candidate elicits more than ‘‘0% immunity’’ against HSV-
2. However, the efficacy of HSV-2 vaccine candidates might be
more clearly defined on a scale of 0 to 100% immunity against
HSV-2. Given that animals latently infected with wild-type HSV
are resistant to superinfection [62,63,64], the efficacy of HSV-2
vaccine candidates could be described in terms of ‘‘% immunity’’
relative to such a positive control. In the current study, we describe
the efficacy of the HSV-2 0DNLS vaccine candidate in such terms
(Fig. 6A, 6B). Specifically, a single exposure to HSV-2 0DNLS
elicited a gD2-antibody response that was 4% of that observed in
wild-type HSV-2 MS latently infected mice (Fig. 6A). Likewise,
HSV-2 0DNLS showed promise as a vaccine candidate because
recipient mice survived lethal HSV-2 MS challenge at the same
100% frequency as HSV-2 MS latently infected mice (Fig. 6B). We
propose that future vaccine studies might benefit from the
inclusion of such a positive control that helps define the ‘‘100%
target value’’ of a bona fide protective immune response against
HSV-2.
Safety concerns surrounding a vaccine based on a
live-attenuated a-herpesvirus?
Many questions remain to be addressed about a live-attenuated
HSV-2 vaccine strain. Is it possible that a live-attenuated virus
such as HSV-2 0DNLS may recombine with endogenous or
superinfecting HSV-2 viruses? Would HSV-2 0DNLS establish
latent infections in vaccine recipients, or reactivate from the latent
state? These are important questions that merit further study.
However, an initial risk-benefit analysis may be performed in light
of clinical experience with the live VZV vaccine. Like HSV-2,
VZV is an a-herpesvirus that establishes life-long infections in
human neurons. Due to the extensive similarity between these
viruses, the safety concerns surrounding a live HSV-2 vaccine
strain are similar to the Oka vaccine strain of VZV.
In the .20-year history of vaccinating against chickenpox,
recombination between the VZV Oka strain and wild-type VZV
has not been reported as a clinical problem. Rather, the major
problem is that the VZV Oka strain may produce disease in
recipients that are severely immunocompromised [27]. While the
VZV Oka strain may establish latent infections in human neurons
and reactivate from the latent state [28], clinical experience
suggests that the risks associated with this live VZV vaccine are
outweighed by the benefits of not leaving a population susceptible
to the .90% risk of being infected with wild-type VZV [65]. If
clinical experience with the VZV Oka strain is any indication,
then the risks associated with a live-attenuated HSV-2 vaccine
strain would likely be preferable to the current situation in which
wild-type HSV-2 is carried by ,1 billion people, and ,20 million
people are newly infected with these disease-causing strains of
HSV-2 each year.
Conclusion
Most vaccines that have succeeded in preventing viral disease
have been based upon live, replicating viruses. Millions of children
receive vaccines every year that contain live-attenuated variants of
poliovirus, mumps virus, measles virus, rubella virus, and VZV.
Despite these successes, efforts to develop a genital herpes vaccine
have primarily focused on non-replicating HSV-2 vaccine
candidates such as gD2-protein subunits [15,16,66,67,68] and
replication-defective HSV-2 viruses [17,18,61,69]. These ap-
proaches are extraordinarily safe, but have not slowed the spread
of genital herpes. Perhaps it is time to consider the possibility that
a live-attenuated HSV-2 vaccine strain might be more effective.
Deletion of conserved regions of ICP0 is a feasible approach to
obtain a new class of live-attenuated HSV-2 vaccine strains that is
safe in theory and practice due to their exquisite sensitivity to
repression by the innate IFN system of the animal host. Therefore,
we conclude that HSV-2 ICP0
2 mutant viruses merit further
consideration for their potential to prevent the spread of HSV-2
and genital herpes in the human population.
Materials and Methods
Ethics Statement
Mice were handled in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals. This
study was approved by the Southern Illinois University School of
Medicine Laboratory Animal Care and Use Committee in August
2008, and was assigned Protocol Numbers #205-08-018 and
#205-08-019. These protocols remain active and are associated
with an NIH-funded grant for the ‘‘Development of an Effective
Genital Herpes Vaccine (R21 AI081072).
Cells and viruses
Vero cells and U2OS cells were obtained from the American
Type Culture Collection (Manassas, VA), and High Five
TM insect
cells were obtained from Invitrogen Corporation (Carlsbad, CA).
The ICP0-complementing L7 cell line [70] was kindly provided by
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in Dulbecco’s Modified Eagle’s medium supplemented with 5%
fetal bovine serum and antibiotics. The HSV-2 recombinant
viruses used in this study were derivative of HSV-2 MS (American
Type Culture Collection). Most HSV-2 lab strains and HSV-2
clinical isolates grow to ,100-fold lower titers than HSV-1. To
circumvent this problem, all HSV-2 viruses were propagated in
U2OS cells at 34uC following inoculation with a multiplicity of
infection of 0.01 pfu per cell, which generally resulted in an ,10-
fold increase in HSV-2 titers. For both wild-type HSV-2 and
HSV-2 ICP0
2 mutant viruses, viral stocks were generated for
animal experiments that were concentrated 10-fold by ultracen-
trifugation to achieve a minimum titer of 3610
7 pfu/ml. An HSV-
2 glycoprotein D-expressing baculovirus was used to purify the
gD-2 306t protein [50], and was generously provided by Dr. Gary
Cohen and Dr. Roslyn Eisenberg (University of Pennsylvania).
Plasmid precursors of HSV-2 recombinant viruses
A plasmid template for mutagenesis of the HSV-2 ICP0 gene
was derived, as follows. An 11.5 kb HindIII – KpnI DNA
fragment was subcloned from wild-type HSV-2 MS genomic DNA
into a pUC18 plasmid vector. This DNA fragment encompassed
the long-internal repeat (IRL) of the HSV-2 genome, and spanned
bases 117,071–128,610 (Genbank #NC_001798). The resulting
plasmid, pHSV2-RL-UL56, contained the HSV-2 ICP0 gene but
was too large for mutagenesis of the ICP0 gene. Excess DNA
sequence was removed via a HindIII - MluI deletion (D117,071–
120,806), and a subsequent AgeI - KpnI deletion (D126,058–
128,610) to obtain pUC-HSV-2-ICP0, which contained bases
120,807–126,057 of the HSV-2 genome. Each mutant allele of the
ICP0 gene was constructed in this background, as follows.
i. p0D104: The plasmid p0D104 was created by replacing the
NotI to BamHI fragment that spans codons 19 to 104 of the HSV-
2 ICP0 gene (bases 124,229–124, 893) with a GFP coding sequence
flanked by matching NotI and BamHI restriction sites. This GFP
coding sequence was generated by PCR amplification off of the
template peGFP-N1 (Clontech Laboratories) using the following
oligonucleotide primers: NotI-GFP-a primer: 59 – ccgagcggccgct-
gagcaagggcgaggagctgt - 39 and BamHI-GFP-b primer: 59- cc-
acaggatcccagctcgtccatgccgagag - 39. Upon sub-cloning of the
PCR-amplified GFP coding sequence into pUC-HSV2-ICP0, the
resulting plasmid p0D104 possessed an open-reading-frame that
encoded amino acids 1 to 18 of HSV-2 ICP0, GFP, and amino
acids 19 to 825 of ICP0 (Fig. 1A, 1B).
ii. p0DRING: The plasmid p0DRING was derived from
p0D104 by deleting the DNA sequence between a BamHI and
PmlI restriction site that spanned codons 105 to 162 (bases
124,055–124,229). The resulting plasmid p0DRING possessed an
open-reading-frame that encoded amino acids 1 to 18 of HSV-2
ICP0, GFP, and amino acids 163 to 825 of ICP0 (Fig. 1A, 1B).
iii. p0D254: The plasmid p0D254 was created by a BamHI to
PstI deletion of codons 105 to 254 in p0D104. This deletion
resulted in a translational frameshift, such that codons 255 to 825
of ICP0 were not in the correct open-reading frame. Consequent-
ly, the plasmid p0D254 encoded amino acids 1 to 18 of HSV-2
ICP0 and GFP (Fig. 1A, 1B).
iv. p0D810: The plasmid p0D810 was created by replacing a
NotI to AscI fragment that spans codons 19 to 810 of the HSV-2
ICP0 gene (bases 121,927–124, 893) with a GFP coding sequence
flanked by matching NotI and AscI restriction sites. This GFP
coding sequence was generated by PCR amplification off of the
template peGFP-N1 (Clontech Laboratories) using the following
oligonucleotide primers: NotI-GFP-a primer: 59 – ccgagcggccgct-
gagcaagggcgaggagctgt - 39 and AscI-GFP- b primer: 59- gcgcg-
ggcgcgcccagctcgtccatgccgag-39. Upon sub-cloning of the PCR-
amplified GFP coding sequence, the resulting plasmid p0D810
possessed an open-reading-frame that encoded amino acids 1 to 18
of HSV-2 ICP0, GFP, and amino acids 811 to 825 of ICP0
(Fig. 1A, 1B).
v. p0DNLS: The plasmid p0DNLS was derived from p0D104
by deleting DNA sequence between PpuMI and XhoI restriction
sites that spanned codons 489 to 694. The plasmid p0DNLS
possessed an open-reading-frame that encoded amino acids 1 to 18
of HSV-2 ICP0, GFP, amino acids 105 to 488 and amino acids
695 to 825 of ICP0 (Fig. 1A, 1B).
vi. Plasmid precursor of HSV-2 MS-GFP: The plasmid
pUC-DLAT-GFP was derived from the parent plasmid pHSV2-
RL-UL56, as follows. Excess DNA sequence was removed via a
SapI - XhoI deletion to derive a plasmid, pUC-HSV-2 LAT, that
contained bases 117,071–122,280 of the HSV-2 genome, which
spanned most of HSV-2’s LAT gene. A CMV-GFP expression
cassette was subcloned from another plasmid into PvuII and BspEI
restriction sites that flanked the transcriptional start site of HSV-
2’s LAT gene. Hence, a CMV-GFP expression cassette was placed
in the same orientation of the LAT gene (i.e., antisense to the ICP0
gene) and replaced the equivalent of bases 119,359–119,530 of the
internal RL region of the HSV-2 genome (Fig. S3).
Construction and isolation of HSV-2 recombinant viruses
Infectious HSV-2 DNA was prepared by a protocol that relies
upon dialysis to minimize shearing of genome-length HSV-2
DNA; this is a modification of a protocol that was generously
provided by Karen Mossman (McMaster University, Hamilton,
Ontario). Five 100 mm dishes of Vero cells (3610
7 cells) were
inoculated with 2 pfu per cell of HSV-2 strain MS and were
incubated overnight at 34uC. After 24 hours, cells were scraped,
centrifuged, rinsed with PBS, resuspended in 7.0 ml of 200 mM
EDTA pH 8.0, and transferred into a 15 ml conical. Proteinase K
(75 ml of 10 mg/ml) and 375 ml of 10% SDS were added to virus-
infected cells, and the tube was incubated in a rotisserie
(hybridization) oven with slow rotation at 50uC for 16 hours.
Proteins were removed by phenol : chloroform extraction, DNA
was transferred into a 0.5–3.0 mL Slide-a-lyzer cassette (10,000
MW cutoff; Pierce Chemical Co., Rockford, IL), dialyzed against
0.16standard saline citrate for 24 hours, aliquoted and frozen at
280uC until use.
Recombinant HSV-2 viruses were generated by co-transfecting
a 60 mm dish containing 8610
5 ICP0-complementing L7 cells
with 1. 2 mg infectious HSV-2 MS DNA and and 2. 1 mg of each
plasmid bearing a GFP
+ mutant allele of the HSV-2 ICP0 gene.
After 6 hours, co-transfection medium was replaced with complete
DMEM containing 1% methylcellulose and GFP
+ plaques were
selected on the stage of a TE2000 fluorescent microscope (Nikon
Instruments, Lewisville, TX). GFP
+ recombinant viruses were
repeatedly passed in ICP0-complementing L7 cells until a uniform
population of viruses was obtained that produced 100% GFP
+
plaques, at which time Southern blot analysis was used to confirm
that the anticipated ICP0
2 mutant allele was transferred into
HSV-2.
Western blot analysis to characterize GFP-tagged, mutant
ICP0 proteins
Vero cell cultures were established at a density of 3610
5 cells
per well in 12-well plates, and were infected at an MOI of 2.5 pfu
per cell. After 18 hours incubation at 34uC, proteins were
harvested using mammalian protein extraction reagent (Pierce
Chemical Co., Rockford, IL) supplemented with 1 mM dithio-
threitol and protease inhibitor cocktail set I (Calbiochem, La Jolla,
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in a 10% polyacrylamide gel with a 4% stacking gel, and were
transferred to nitrocellulose membranes. Protein blots were
blocked in phosphate-buffered saline (PBS) containing 5% nonfat
dry milk, and were incubated overnight at 4uC in PBS+0.1%
Tween-20+5% nonfat dry milk containing a 1:1000 dilution of a
rabbit polyclonal anti-GFP antibody (Clontech Laboratories Inc.).
Following incubation with primary antibody, membranes were
washed four times with PBS+0.1% Tween-20 (PBS-T), and were
then incubated for 1 hour with a 1:20,000 dilution of goat anti-
rabbit IgG conjugated to the infrared fluorescent dye IRDyeH 680
(LI-COR Bioscience, Lincoln, NE). Protein blots were washed
three times in PBS-T, rinsed in PBS (to remove Tween-20), and
were scanned for two-color fluorescence using the Odyssey
Infrared imaging system, and data were analyzed using Odyssey
application software version 3.0.16 (LI-COR Bioscience).
Southern blot analysis of ICP0 locus in HSV-2 ICP0
2
viruses
Cultures of L7 or Vero cells were established at a density of
1.5610
6 cells per plate in 60 mm dishes, and inoculated with
MOIs of 2.5 pfu per cell for 24 hours at a temperature of 34uC.
DNA was isolated, digested with the restriction enzymes Sac I and
Stu I, and was separated on 1.2% agarose gels, blotted onto Zeta
Probe GT nylon membranes (Biorad Laboratories, Hercules, CA),
and hybridized with radiolabeled oligonucleotides specific for exon
2 of the HSV-2 ICP0 gene 59 –tgaagg tcgtcgtcagagattcc-
cacctcggtctcctcct- 39 or the GFP coding sequence (59-ata-
gacgttgtggctgttgtagttgtactccagcttgtgc-39). Oligonucleotides were
end-labeled with [a-
32P] dATP using terminal deoxynucleotidyl
transferase (Promega Corporation, Madison, WI) and were
hybridized to their target sequence via 16 hours of hybridization
at 37uC in a solution containing 5 ng/ml labeled probe, 7% SDS,
120mM NaH2PO4, and 250mM NaCl. Excess probe was removed
from membranes by sequential rinses in 0.16 standard saline
citrate containing 0.1% SDS. Blots were exposed to phosphor
screens, which were scanned and analyzed with a Cyclone
PhosphorImager and OptiQuant software (Perkin Elmer, Boston,
MA).
Measurements of interferon sensitivity of wild-type
HSV-2 and HSV-2 ICP0
2 viruses
i. Plaque assays. Cultures of ICP0-complementing L7 cells
or Vero cells were established in 6-well plates at a density of
3.5610
5 cells per well in 2.0 ml complete DMEM in the morning.
Six hours later, one-half of Vero cell cultures were treated by the
addition of recombinant IFN-b to achieve a concentration of
200 U/ml, or 0.15 nM (PBL Biomedical Laboratories,
Piscataway, NJ). Sixteen hours later, Vero cells were inoculated
with log-dilutions of HSV-2 MS or each of the HSV-2 ICP0
2
mutant viruses. After allowing 45 minutes for adsorption, the viral
inoculum was replaced with complete DMEM containing 0.5%
methylcellulose. The subset of Vero cell cultures that were pre-
treated with IFN-b were overlaid with complete DMEM
containing 0.5% methylcellulose and 200 U/ml IFN-b. Cultures
were incubated for 72 hours to allow plaques to develop. Cell
monolayers were fixed and stained with a solution of 20%
methanol and 0.1% crystal violet, and plaques were counted.
ii. Growth curves. Cultures of ICP0-complementing L7 cells
or Vero cells were established in 24-well plates at a density of
2610
5 cells per well in 0.5 ml complete DMEM in the morning.
Six hours later, one-half of Vero cell cultures were treated by the
addition of recombinant IFN-b to achieve a final concentration of
200 U/ml (PBL Biomedical Laboratories). Sixteen hours later,
cultures of L7 cells or Vero cells were inoculated with 200 mlo fa
100,000 pfu/ml inoculum of each virus to achieve an MOI of 0.1
pfu per cell. After allowing 45 minutes for adsorption, the viral
inoculum was aspirated, cell monolayers were rinsed with 0.5 ml
of complete DMEM, and each culture received a final volume of
0.5 ml complete DMEM. Vero cell cultures that were pre-treated
with IFN-b received complete DMEM containing 200 U/ml IFN-
b. Cultures were incubated at 37uC and were transferred to a
280uC freezer at 3, 6, 12, 18, 24, 36, or 48 hours p.i. Upon
thawing, viral titers were determined by a microtiter plaque assay
on monolayers of freshly seeded L7 cells.
Inoculation of mice with HSV-2 viruses
Mice were first inoculated with HSV-2 at 6- to 10-weeks of age,
and were handled in accordance with the NIH Guide for the Care
and Use of Laboratory Animals. Female ICR mice were obtained
from Harlan Sprague Dawley (Indianapolis, IN). Female strain
129 mice, rag2
2/2 mice, and stat1
2/2 mice were obtained from
Taconic Farms (Germantown, NY).
Prior to viral inoculation, mice were anesthetized by i.p.
administration of xylazine (7 mg/kg) and ketamine (100 mg/kg).
Ocular inoculation of female mice with HSV-2 viruses was
performed by scarifying the left and/or right corneas with a 26-
gauge needle and by placing 4 ml complete DMEM containing the
stated amount of virus on each scarified eye. Viral titers in the
ocular tear film of mice were determined at times after inoculation
by swabbing the ocular surface of eyes with a cotton-tipped
applicator, and transferring the tip into 0.4 ml complete DMEM.
Viral titers were determined by a 96-well plate plaque assay on
ICP0-complementing L7 cells cultured in complete DMEM
containing 0.5% methlycellulose. After two to three days, cell
monolayers were stained with a solution of 20% methanol and
0.1% crystal violet and plaques were counted.
Fluorescent microscopy of mouse eyes and mouse faces
Fluorescent photographs of the eyes and faces of mice infected
with HSV-2 MS-GFP or HSV-2 ICP0
2 mutant viruses were
obtained using a Nikon TE2000 inverted fluorescent microscope
(Nikon Instruments, Lewisville, Tex.) fitted with an Olympus
DP72 digital camera (Olympus America, Center Valley, PA)
controlled by Olympus DP2-BSW microscope digital camera
software. Mice were anesthetized by i.p. administration of xylazine
(6.6 mg/kg) and ketamine (100 mg/kg) and placed face down on a
clear petri dish. Photographs of eyes were captured with a 46
objective using a constant exposure and lighting conditions.
Photographs of faces are composites of 20 to 30 photographs
captured with a 26objective under constant conditions to record
GFP expression across the entire left side of each mouse’s face. A
single composite of each face was derived by merging individual
images using the photomerge feature of Photoshop CS3 software
(Adobe Systems Incorporated, San Jose, CA).
HSV-2 gD-antibody capture ELISA
Enzyme-linked immunosorbent assay (ELISA) was used to
measure HSV-2 gD (gD2)-specific antibody titers in the serum of
mice, as follows. Mice were bled on Day 60 post-inoculation by
collecting blood from the right retroorbital sinus with heparinized,
Natelson blood collecting tubes. The serum fraction was collected
from centrifuged blood at 18 hours post-collection, and stored at
280uC until used in ELISA.
The coating antigen used in antibody-capture ELISA was a
recombinant protein isolated from High Five
TM insect cells
infected with a gD2-306t-expressing baculovirus; this reagent was
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Eisenberg (University of Pennsylvania, Philadelphia, PA). The
gD2-306t protein was engineered by Nicola, et al. (1996) to possess
an N-terminal honeybee melittin secretion signal in place of gD2’s
native leader peptide, followed by amino acids 25–306 of HSV-2
gD and a C-terminal His6 affinity-purification tag [50]. The gD2-
306t protein was isolated as follows. A flask containing 2610
8
High Five
TM insect cells was inoculated with 2 pfu per cell of
HSV-2 gD2-306t-expressing baculovirus, and incubated while
shaking at 27uC for 48 hours. Baculovirus-infected cells were
removed by centrifugation, and secreted gD2-306t protein was
purifed from supernatants, as follows. Supernatants were dialyzed
against an excess of 20 mM Tris pH 8.0, 300 mM NaCl, and 10%
glycerol overnight, and 10 mM imidazole was added to the
dialyzed supernatant prior to affinity purification on a HisTrap
TM
HP column (GE Healthcare Biosciences, Piscataway, NJ) using an
A ¨KTApurifier
TM fast-performance liquid chromatography system
(GE Healthcare Biosciences). The gD2-306t protein was eluted
from the column with 300 mM imidazole, and purity was verified
at .90% by SDS-PAGE and Coomassie blue staining. Aliquots of
gD2-306t were stored at -80uC.
High-binding EIA 96-well plates (Costar, Corning, NY) were
coated overnight at 4uC with 100 ml per well of sodium carbonate
buffer (pH 9.6) containing 1.5 mg per ml gD2-306t protein [50].
Wells were blocked for 2 hours with 400 ml of 2% dry milk
dissolved in PBS+0.02% Tween-20 (polyoxyethylene-20-sorbitan
monolaurate), hereafter referred to as PBS-T buffer. Mouse serum
was diluted 1:100 in PBS+1% fetal bovine serum+0.02% Tween-
20. After discarding blocking buffer from ELISA plates, duplicate
100-ml samples of 1:100 diluted mouse serum were added to gD2-
306t-coated wells and were incubated for 2 hours. ELISA plates
were rinsed seven times with an excess of PBS-T buffer prior to the
addition of 100 ml secondary antibody diluted 1:2500 in PBS-T
buffer; the secondary antibody was alkaline phosphatase-conju-
gated rabbit anti-mouse c chain (Rockland Immunochemicals,
Gilbertsville, PA). After allowing 1 hour, secondary antibody was
rinsed from plates seven times with PBS-T buffer, and 200 m1o fp -
nitrophenyl phosphate substrate (Sigma Chemical Co., St. Louis,
MO) was added to each well, and colorimetric development
(OD405) was measured after a 30 minute incubation in an ELISA
plate reader (Bio-tek Instruments, Inc., Winooski, VT).
Mathematical and statistical analysis of results
Viral titers were transformed by adding a value of 1 such that all
data could be plotted and analyzed on a logarithmic scale. The
significance of differences in log (IFN sensitivity), log (HSV-2
shedding per eye), log (gD2-antibody), and duration of survival was
compared by one-way analysis of variance followed by Tukey’s
post hoc t-test. The significance of differences in survival frequency
was determined by Fisher’s Exact Test. All statistical analysis was
performed using Instat v3.0 software (Graphpad Software, La
Jolla, CA).
The quantitative relationship between color development in
ELISA and abundance of anti-gD2 antibody was defined, as
follows. A standard curve was developed based on dilutions of
pooled antisera from HSV-2 MS latently infected mice that
spanned dilutions of 1:46 to 1:215,000. A hyperbolic tangent-
based standard curve [71] of the form x=x50+DX N arctan
OD405{y50
DY

was used to calculate gD2-antibody abundance
(Fig. S3). Serum samples of naı ¨ve mice were used to define the
background of the gD2-antibody capture assay, and the abun-
dance of gD2-antibody in all serum samples was normalized to this
background value.
Supporting Information
Figure S1 Amino acids in HSV-1 ICP0 and HSV-2 ICP0 are
aligned to demonstrate the basis for concluding that the RING
finger region is conserved at a level of 87% amino acid homology
(shown in blue), the nuclear localization signal (NLS) region which
includes flanking phosphorylation sites is conserved at a level of
65% amino acid homology (shown in brown), and the C-terminal
oligomerization domain is conserved at a level of 86% amino acid
homology (shown in red).
Found at: doi:10.1371/journal.pone.0012251.s001 (0.17 MB TIF)
Figure S2 Description of HSV-2 MS-GFP. (A) Schematic of
CMV-GFP expression cassette introduced into the 59 end of HSV-
2’s non-essential LAT gene. The CMV-GFP expression cassette
was derived from the peGFP-N1 plasmid (Clontech Laboratories,
Mountain View, CA) and replaced bases 119,359–119,530 of the
LAT promoter. (B) Southern blot analysis of NotI-digested
plasmid DNA (shown on left) or NotI-digested viral DNA (shown
on right). The plasmids pUC-HSV-2-LAT contains most of the
LAT gene derived from HSV-2 MS, and the plasmid pUC-
deltaLAT-GFP was the plasmid precursor of HSV-2 MS-GFP.
The NotI-digested DNA shown on the right was derived from
Vero cells that were uninfected (UI) or were inoculated with 2.5
pfu per cell of HSV-2 MS or HSV-2 MS-GFP. A LAT promoter-
specific oligonucleotide (59-ccctgtgtcattgtttacgtggccgcgggccagca-
gacgg-39) was hybridized to Southern blots, which hybridized
upstream of the PvuII - BspEI deletion in the LAT gene, and
which served to verify that the CMV-GFP expression cassette in
pUC-deltaLAT-GFP was transferred intact into the correct locus
in HSV-2 MS-GFP. A replicate blot (not shown) verified that the
anticipated PvuII - BspEI fragment was deleted from the LAT
gene of HSV-2 MS-GFP.
Found at: doi:10.1371/journal.pone.0012251.s002 (0.52 MB TIF)
Figure S3 Standard curve used to measure the abundance of
gD2-antibody in mouse serum. (A) Photograph of color develop-
ment in antibody capture ELISA wells coated with HSV-2
glycoprotein D (gD2) that received a 0.33-log dilution series of
mouse anti-HSV-2 antiserum. The dilution factor of serum is
shown above (red text), and the relative abundance of gD2-
antibody is expressed below in terms of the logarithmic increase
over the background of the assay (black text). (B) The relationship
between the logarithm (gD2-antibody abundance) and OD405
color development was described using a hyperbolic tangent-based
standard curve. The equation, shown in panel B, relies on four
constants defined by the standard curve, and which are briefly
explained as follows: the data point x50, y50 represents the
midpoint of the hyperbolic tangent (S-shaped curve); 2deltaX
equals the range of gD2-antibody abundance over which 76% of
the change in OD405 occurs; and deltaY equals one-half of the
total change in OD405 that occurs. The curve-fitting methods
used to derive hyperbolic tangent-based standard curves are
described elsewhere by Halford, et al. [72]. Closed yellow circles
indicate the actual OD405 (yellow color) observed, and the ‘+’
symbols represent the values of OD405 predicted by the
hyperbolic tangent equation over a 10,000-fold range of gD2-
antibody concentrations. This standard curve was used to calculate
gD2-antibody abundance in the serum samples shown in
Figure 6A.
Found at: doi:10.1371/journal.pone.0012251.s003 (2.74 MB TIF)
Figure S4 Enlarged faces of mice infected with HSV-2 MS-GFP
or HSV-2 0deltaNLS. Enlargements of images shown in Figure 8B.
Found at: doi:10.1371/journal.pone.0012251.s004 (9.38 MB TIF)
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